Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: A systematic review and meta-analysis

Gastric Cancer

Volumn 14, Issue 1, 2011, Pages 50-55

  Montagnani, Francesco ^a   Turrisi, Gina ^a   Marinozzi, Claudio ^b   Aliberti, Camillo ^c   Fiorentini, Giammaria ^a  

^a S Giuseppe Hospital   (Italy)

^b Tuscany Network for Integrative Medicine   (Italy)

^c Hospital of the Delta   (Italy)

Author keywords

Advanced gastric cancer; Cisplatin; Oxaliplatin; Systematic review

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

CISPLATIN; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 79953027573     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-011-0007-7     Document Type: Article

References (20)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 15761078 10.3322/canjclin.55.2.74 (Pubitemid 40372904)
2. V Valentini F Cellini BD Minsky GC Mattiucci M Balducci G D'Agostino, et al. 2009 Survival after radiotherapy in gastric cancer: systematic review and meta-analysis Radiother Oncol 92 2 176 183 19586672 10.1016/j.radonc.2009.06.014
3. D Cunningham WH Allum SP Stenning JN Thompson CJ Van de Velde M Nicolson, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 1 11 20 16822992 10.1056/NEJMoa055531 1:CAS:528:DC%2BD28Xms1Chsrw%3D
4. AD Wagner W Groethe J Haerting G Kleber A Grothey WE Fleig 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909 16782930 10.1200/JCO.2005.05. 0245 1:CAS:528:DC%2BD28XntV2gs7s%3D (Pubitemid 46630593)
5. N Starling S Rao D Cunningham T Iveson M Nicolson F Coxon, et al. 2009 Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Studies Group J Clin Oncol 27 23 3786 3793 19398575 10.1200/JCO.2008.19.4274 1:CAS:528:DC%2BD1MXhtFaitr3E
6. SG Chaney SL Campbell E Bassett Y Wu 2005 Recognition and processing of cisplatin- and oxaliplatin-DNA adducts Crit Rev Oncol Hematol 53 1 3 11 15607931 10.1016/j.critrevonc.2004.08.008 (Pubitemid 39656106)
7. DY Kim JH Kim SH Lee TY Kim DS Heo Y Bang, et al. 2003 Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer Ann Oncol 14 3 383 387 12598342 10.1093/annonc/mdg106 1:STN:280:DC%2BD3s%2Fos1Gmsw%3D%3D (Pubitemid 36367414)
8. C Louvet T André JM Tigaud E Gamelin JY Douillard R Brunet, et al. 2002 Phase II study of oxaliplatin, fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 23 4543 4548 12454110 10.1200/JCO.2002.02.021 1:CAS:528:DC%2BD38XovVeisLw%3D (Pubitemid 35407422)
9. Al-Batran SE, Atmaca A, Jaeger E et al. Phase II trial of biweekly infusional fluorouracil, folinic acid and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22(4):685-63.
10. J Souglakos K Syrigos A Potamianou A Polyzos I Boukovinas N Androulakis, et al. 2004 Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial Ann Oncol 15 8 1204 1209 15277259 10.1093/annonc/mdh312 1:STN:280:DC%2BD2cznt1WmtA%3D%3D (Pubitemid 39206258)
11. P Correale F Fulfaro S Marsili G Cicero E Bajardi C Intrivici, et al. 2005 Gemcitabine plus oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer Cancer Chemother Pharmacol 56 6 563 568 16041610 10.1007/s00280-005-1024-1 1:CAS:528:DC%2BD2MXhtVKqu7bF (Pubitemid 41430301)
12. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon, et al. 2008 Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced gastric cancer N Engl J Med 358 36 46 18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
13. AFC Okines AR Norman P McCloud YK Kang D Cunningham 2009 Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophagogastric cancer Ann Oncol 20 1529 1534 19474114 10.1093/annonc/mdp047 1:STN:280:DC%2BD1MrnsVGhug%3D%3D
14. SE Al-Batran JT Hartmann S Probst H Schmalenberg S Hollerbach R Hofheinz, et al. 2008 Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 26 9 1435 1442 18349393 10.1200/JCO.2007.13.9378 1:CAS:528:DC%2BD1cXkslKqsL8%3D
15. I Popov L Radosevic-Jelic S Jezdic M Milovic N Borojevic S Stojanovic, et al. 2008 Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer J BUON 13 505 511 19145671 1:STN:280:DC%2BD1M%2Fnt1OmsA%3D%3D
16. RM Goldberg I Tabah-Fisch H Bleiberg A de Gramont C Tournigand T Andre ML Rothenberg E Green DJ Sargent 2006 Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer J Clin Oncol 24 4085 4091 16943526 10.1200/JCO.2006.06.9039 1:CAS:528:DC%2BD28XhtVantb3P (Pubitemid 46622283)
17. Bria E, Gralla RJ, Raftopoulos H, Giannarelli D. Comparing two methods of meta-analysis in clinical research-individual patient data-based (IPD) and literature-based abstracted data (AD) methods: analyzing five oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs). J Clin Oncol. 2007;25(18S) (Suppl Abstr 6512).
18. GH Lyman NM Kurderer 2005 The strengths and limitations of meta-analyses based on aggregate data BMC Med Res Methodol 5 14 15850485 10.1186/1471-2288-5- 14 (Pubitemid 40918747)
19. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, Schumacher G. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2009;27(15 s) (Suppl Abstr 4540).
20. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol. 2009;27(18 s):(Suppl abstr LBA4509).